Open Access
CC BY 4.0 · Glob Med Genet 2023; 10(04): 388-394
DOI: 10.1055/s-0043-1777789
Original Article

Integrative Analysis of PAIP2B to Identify a Novel Biomarker for Pancreatic Ductal Adenocarcinoma

Autoren

  • Yaoxian Xiang

    1   Department of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, China
  • Li Wang

    1   Department of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, China
  • Yurong Cheng

    1   Department of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, China
  • Huanjuan An

    2   Department of Hematology, Peking University Shougang Hospital, Beijing, China
  • Chan Zhang

    1   Department of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, China
  • Jing Wang

    1   Department of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, China
  • Yingying Tong

    1   Department of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, China
  • Dong Yan

    1   Department of Oncology, Beijing Luhe Hospital Affiliated to Capital Medical University, Beijing, China

Funding This work was supported by the “R&D Program of Beijing Municipal Education Commission (KM202010025005),” “Beijing Municipal Natural Science Foundation (7222100),” and TongZhou District Science and Technology Plan Project (KJ2022CX021).

Abstract

The aim of the study was to evaluate the potential diagnostic and prognostic value of gene, Poly A-Binding Protein Interacting Protein 2B (PAIP2B) in pancreatic cancer. We used the gene expression data and clinical information of pancreatic adenocarcinoma patients from The Cancer Genome Atlas database and Gene Expression Omnibus database to analyze the expression of PAIP2B in pancreatic cancer samples, and validated the expression of PAIP2B in tumor tissue, using bioinformatics technology to explore the prognostic value of PAIP2B and its possible biological function. A significantly lower level of PAIP2B was observed in pancreatic cancer patients than in controls, and validated by immunohistochemistry. PAIP2B reduced the proliferation and invasion of cancer cells and had a significantly high expression in early stage. Patients with lower levels of PAIP2B had a significantly shorter median survival time than those with higher levels. DNA demethylation played an important role in PAIP2B expression. In addition, PAIP2B expression was significantly associated with the tumor-infiltrating immune cells, especially T cells CD8, T cells CD4 memory resting, macrophages M0, and dendritic cells resting. Our study also found that PAIP2B regulated miRNA function leading to disease progression in pancreatic cancer patients. Our study explored the potential value of PAIP2B as a biological link between prognosis and pancreatic cancer, and provided reference for the follow-up study on the role of PAIP2B in pancreatic cancer.

Data Availability

The data underlying this article are available in TCGA database (https://tcga-data.nci.nih.gov/tcga/) and the GEO database (https://www.ncbi.nlm.nih.gov/geo/).


Authors' Contributions

The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.




Publikationsverlauf

Artikel online veröffentlicht:
19. Dezember 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany